Four genes were identified as high-priority targets for migraine treatment, with a posterior probability greater than 0.90 of sharing causal variants with migraine risk.
Causal effects of 9,117 unique genetic variants on migraine were assessed across 14 immune cell types.
Differential expression patterns of the identified genes were observed in various cell types and migraine-related conditions.
Safety assessments indicated a low risk of off-target effects in multiple body systems for the identified targets.
Three repurposable drug candidates were identified, including one approved drug and two investigational drugs, with potential therapeutic applications for migraine.
Simplified
BACKGROUND: Migraine, a complex neurovascular disorder, is closely associated with neuroinflammation and immune dysregulation. However, the high heterogeneity of immune cell populations means that the specific cellular immune mechanisms driving migraine susceptibility remain unclear.
METHODS: We integrated single-cell expression quantitative trait locus () data by applying single-cell Mendelian randomization (Mendelian randomization applied at single-cell resolution, scMR) and colocalization analyses to systematically explore immune-mediated regulatory mechanisms underlying migraine and to identify potential therapeutic targets.
RESULTS: We assessed the causal effects of 9,117 unique sc-eQTLs on migraine across 14 immune cell types. Four genes (PRDM11, VIM, FGFRL1, C6orf25) were identified as high-priority targets. Colocalization analysis revealed a high probability (posterior probability PP.H4 > 0.90) that these genes share causal variants with migraine genome-wide association study (GWAS) signals. Single-cell RNA sequencing (scRNA-seq) analyses revealed differential expression patterns of these genes across cell types and migraine-related states. Safety assessments based on phenome-wide association studies () showed a low risk of off-target effects in multiple body systems, thus supporting their safety as therapeutic targets. Mapping these targets to a database of known drugs identified three repurposable drug candidates (one approved and two investigational) with therapeutic potential for migraine.
CONCLUSIONS: This study establishes an extensible multi-omics analytical framework, providing novel insights into the immunogenetic basis of migraine. Furthermore, it successfully identified repurposable candidate drugs targeting key pathogenic genes, offering new perspectives for developing novel immunomodulatory therapeutic strategies for migraine.
Key numbers
1.001
Increased Migraine Risk per Gene Expression Unit (PRDM11)
Odds ratio for PRDM11 expression in NK cells.
1.002
Increased Migraine Risk per Gene Expression Unit (C6orf25)
Odds ratio for C6orf25 expression in B IN cells.
0.998
Protective Effect per Gene Expression Unit (VIM)
Odds ratio for VIM expression in CD8 ET cells.
Full Text
We can’t show the full text here under this license.
Declarations. Ethics approval and consent to participate: No need for ethical approval as used of anonymous open data. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
